The following is a summary of the Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript:
Financial Performance:
Net revenue for Q3 2024 was $29,000, a decrease from $42,000 in the same period a year ago.
Total operating expenses for Q3 2024 were $8.9 million, up 8% from $8.2 million in Q3 2023.
Net loss for Q3 2024 increased to $7.9 million from $7.2 million in Q3 2023.
Business Progress:
Focused on publication of clinical trial results and expanding test adoption and payer coverage.
Launched educational campaigns with significant engagement and initiated direct-to-consumer sales through new online platforms.
Continued growth in visibility and adoption through media campaigns and social media presence.
Opportunities:
Addressing increased rates of preterm births in the U.S., a significant health care challenge, via educational and awareness campaigns.
Expanding direct-to-consumer access to PreTRM tests, enhancing potential for revenue growth.
Risks:
Slow scaling of AI services may delay expected revenue growth from these innovations.
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
